-
Recursion Q1 net loss narrows to $117.5M; REC-1245 safety data positive, REC-4539 dosed
Net loss of $117.5M vs $202.5M YoY; revenue $6.5M, down 56% YoY on lower Roche milestone phasing.
-
Recursion founder & Chair Chris Gibson will not stand for re-election; to become advisor
Chris Gibson, Ph.D., founder and Chair, will not seek re-election at 2026 Annual Meeting (June 2026).
-
Recursion appoints Vicki Goodman as CMO effective April 6, 2026; David Mauro transitions out
Dr. Goodman joins from Mural Oncology as CMO; prior executive roles at Exelixis, Merck, BMS, and GSK.
-
Recursion Q4 revenue $35.5M; first AI-driven clinical validation in FAP; cash runway to 2028
Q4 revenue $35.5M (up from $4.5M YoY); net loss $108.1M vs $178.9M; cash $753.9M.
-
Recursion releases updated investor presentation for JP Morgan Healthcare Conference
Presentation dated January 12, 2026, used at JP Morgan Healthcare Conference and investor meetings.
-
Recursion reports positive Phase 1b/2 data for REC-4881 in FAP: 75% show polyp burden reduction
75% of evaluable patients reduced total polyp burden at 12 weeks; median reduction 43%.
-
Recursion issues 7.1M shares to Tempus AI for license fees; registers for resale
Issued 7,088,742 Class A shares to Tempus AI on Nov 24, 2025 as payment for annual license fees.
-
Recursion appoints Najat Khan as CEO effective Jan 1, 2026; Q3 net loss $162.3M
Najat Khan succeeds Chris Gibson as CEO and President effective Jan 1, 2026; Gibson becomes Chairman.
-
Roche exercises option for Recursion's Microglia Map; $30M fee
Roche exercised option for a first-of-its-kind whole genome map of brain immune cells (Microglia Map) from Recursion.
-
Recursion issues 2.4M contingent shares to Rallybio after GLP tox milestone
Milestone triggered by initiation of GLP toxicology study on August 25, 2025.
-
Recursion Q2 2025: $7M Sanofi milestone; REC-1245 and REC-617 trial updates
Announced $7 million milestone from Sanofi partnership for partnered discovery program.
-
Recursion acquires full ownership of oral ENPP1 inhibitor program from Rallybio
Buys Rallybio's 50% stake in ENPP1 JV, gaining full rights to REV102 for hypophosphatasia.
-
Recursion Pharmaceuticals stockholders elect directors, approve exec comp, ratify auditor at 2025 meeting
Elected Zachary Bogue (242.3M for, 4.0M withheld), Zavain Dar (203.3M for, 42.9M withheld), Robert Hershberg (233.5M for, 12.8M withheld) as Class I directors.
-
Recursion cuts workforce ~20%, extends cash runway to Q4 2027; $11M severance charges
Workforce reduction of ~20%; expects ~$11M in severance and related costs in 2025.
-
Recursion registers 4.26M shares for resale by Tempus Labs under prior license agreement
Filed prospectus supplement to register 4,260,927 shares of Class A common stock for resale by Tempus Labs, Inc.
-
Recursion Q1 net loss widens to $202.5M; Sanofi milestone $7M; pipeline refocused
Q1 net loss $202.5M vs $91.4M YoY; revenue $15M (up from $14M).
-
Recursion appoints former FDA Principal Deputy Commissioner Dr. Bumpus and Mammoth Biosciences COO/CFO Sun to board
Elaine Sun and Dr. Namandjé Bumpus appointed to Board effective March 15, 2025, expanding board from 8 to 10.
-
Recursion reports Q4 net loss $178.9M, FY2024 net loss $463.7M; cash runway into 2027
Cash, cash equivalents and restricted cash $603.0M at Dec 31, 2024 vs $401.4M at Dec 31, 2023; runway extended into 2027.
-
Recursion Pharmaceuticals releases updated investor presentation for JP Morgan Healthcare Conference
Investor presentation dated January 13, 2025 attached as Exhibit 99.1
-
Recursion registers 3.5M shares for resale by Tempus Labs as license fee payment
Recursion filed prospectus supplement to register 3,498,393 shares for resale by Tempus Labs.
-
Recursion CFO Ben Taylor gets $5M equity grant, enhanced vesting on Exscientia awards
Ben Taylor (CFO) enters employment letter with Exscientia AI Ltd, base salary £400K/year.
-
Recursion completes Exscientia acquisition; pro forma shows increased net losses
Total purchase price ~$635.9M; transaction closed Nov 20, 2024.
-
Recursion issues 102.3M shares to close Exscientia acquisition
102,298,808 shares of Class A common stock issuable to Exscientia shareholders and option/RSU holders.
-
Recursion completes Exscientia acquisition; issues 102M shares, names new CFO
Acquisition of Exscientia effective Nov 20, 2024 via UK scheme; 0.7729 Recursion shares per Exscientia share; 102,138,419 shares issued.
-
Recursion & Exscientia shareholders approve combination; close expected Nov 20
Overwhelming shareholder approval from both Recursion (RXRX) and Exscientia (EXAI) for the proposed combination.
-
Recursion shareholders approve stock issuance for Exscientia acquisition
Shareholders voted 99.77% in favor (250.9M votes for) of issuing Class A common stock for the Exscientia acquisition.
-
Recursion amends Exscientia acquisition to clarify post-closing board appointments
Amendment lets Exscientia designate one board member (subject to Recursion board approval) effective at closing; a second member if mutually agreed.
-
Recursion Q3 revenue $26.1M, net loss $95.8M; Exscientia merger on track
Revenue surged to $26.1M from $10.5M YoY; net loss $95.8M vs $93.0M; no EPS provided.
-
FDA clears IND for Recursion's REC-1245, a first-in-class RBM39 degrader for solid tumors/lymphoma
FDA cleared IND for REC-1245, a potential first-in-class RBM39 degrader for biomarker-enriched solid tumors and lymphoma.
-
Recursion reports top-line SYCAMORE data, files Exscientia financials for proposed merger
SYCAMORE Phase 2 trial for REC-994 in symptomatic CCM patients: top-line results announced Sept 3, 2024 (press release as Exhibit 99.2).
-
Evotec commits ~11% Exscientia shares to Recursion deal; total committed ~53%
Evotec SE, holding ~11% of Exscientia shares, executed irrevocable undertaking on Aug 28 to vote in favor of Recursion acquisition.
-
Recursion acquires Exscientia in stock deal; director Burrell resigns; Q2 results reported
Recursion to acquire Exscientia via UK scheme of arrangement; Exscientia shareholders get 0.7729 Recursion shares per share.
-
Recursion announces Roche exercises option for first Neuroscience Phenomap; receives $30M fee
Roche exercised option for first Neuroscience Phenomap under 2021 Collaboration Agreement.
-
Recursion prices $200M public offering of 30.8M shares at $6.50 per share
Gross proceeds ~$200M before underwriting discounts and estimated offering expenses.
-
Recursion gives guidance on seven clinical readouts within ~18 months and Bayer LOWE partnership
Topline Phase 2 data for REC-994 (CCM) in Sep 2024; prelim Phase 2 data for REC-2282 (NF2) in Q4 2024.
-
Recursion annual meeting elects Class III directors, approves say-on-pay
Blake Borgeson, Ph.D. elected as Class III director with 165,914,956 votes for, 26,093,759 withheld.
-
Recursion appoints Robert Hershberg as new board chair; Martin Chavez to exit at 2024 annual meeting
Martin Chavez not standing for re-election; term ends at 2024 Annual Meeting; no disagreement with company.